Hear What Colin Hill had to say to Sidley on AI Use in Drug Discovery

Sydley 300x300 1

Stephen Abreu, Sidley partner, talks to our Colin Hill about how the use of AI is revolutionizing the biotech space. Colin explains how our ability to predict and understand the actions of biological systems has historically been limited because of the complexity of “genetic circuitry,” but AI has allowed us to develop a more quantitative […]

Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease

Webinar Video

Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers. In […]

Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer

ServierAitia

The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins. Read more on the latest […]

Colin Hill Weighs in on the Future of Drug Discovery on the Patients Rising Podcast

Screenshot 2023 06 28 at 12.13.02 PM

Our CEO, Colin Hill was a special guest on the Patients Rising Podcast. In this week’s episode, Colin passionately shared his beliefs and vision for the future of medical research, highlighting the transformative potential of AI-powered clinical trials and the revolutionary power of Digital Twins. Tune in to the podcast episode now and discover how Digital […]

Open to Debate: Is the FDA’s Caution Hazardous to your Health?

Aspen 1

During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio had run a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to […]